FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078235523> ?p ?o ?g. }

• W2078235523 endingPage "134" @default.
• W2078235523 startingPage "126" @default.
• W2078235523 abstract "Background: We have developed a novel liquid intravenous immunoglobulin (IVIG-F10). It consists of a nanofiltered 12% immunoglobulin G (IgG) solution, stabilized with nicotinamide, L-proline and L-isoleucine. The efficacy, tolerability, safety, and pharmacokinetics of this product were assessed in patients with chronic immune thrombocytopenic purpura (ITP) and primary humoral immunodeficiencies (PID). Patients and Methods: 33 chronic ITP patients with platelet counts of < 20 × 109/l were treated with IVIG-F10 or Sandoglobulin at doses of 0.4 g/kg body weight on 5 consecutive days. The primary efficacy endpoint was an increase in platelet counts to ≧50 × 109/l. Secondary endpoints were time to and duration of platelet response and regression of bleeding. 34 PID patients with X-linked agammaglobulinemia, common variable immunodeficiency or IgG subclass deficiency were treated for 6 months with IVIG-F10 or Sandoglobulin at doses of 0.3–0.8 g/kg, infused at 3- or 4-week intervals. The primary efficacy endpoint was the number of days absent from school/work. Secondary endpoints were feeling of well-being, days of hospitalization, and use of antibiotics. Results: In ITP patients, the primary endpoint was met by 12/16 patients on IVIG-F10 and by 12/17 patients on Sandoglobulin (p = 1.000). Results of the secondary endpoints were comparable in the two study groups. In the PID study, 10/17 patients on IVIG-F10 and 9/17 patients on Sandoglobulin missed days at school/work, with monthly mean absences of 0.7 and 0.6 days (p = 0.746), respectively. There were no significant differences in the outcome of the secondary endpoints. Pharmacokinetics showed constant peak and trough serum IgG levels in PID patients. The median half-life (t1/2) of IgG was 33 days in the IVIG-F10 group and 41 days in the Sandoglobulin group. For anti-HBsAg, median t1/2 values were shorter, i.e. 17 and 19 days for IVIG-F10 and Sandoglobulin, respectively. In the ITP study, adverse events related to study drug were suspected in 9 and 14 patients treated with IVIG-F10 and Sandoglobulin, respectively; in the PID study adverse events occurred in 8 and 9 patients, respectively. Viral safety was ascertained in both studies by serology supplemented with nucleic acid amplification testing. Serum levels of the stabilizers transiently increased after infusion of IVIG-F10, but were back to baseline at the following day. Conclusions: The clinical studies in patients with chronic ITP and PID showed that the efficacy, tolerability, safety, and pharmacokinetics of IVIG-F10 were comparable to the properties of Sandoglobulin." @default.
• W2078235523 created "2016-06-24" @default.
• W2078235523 creator A5004237078 @default.
• W2078235523 creator A5006932938 @default.
• W2078235523 creator A5029031558 @default.
• W2078235523 creator A5031052014 @default.
• W2078235523 creator A5034923377 @default.
• W2078235523 creator A5050816060 @default.
• W2078235523 creator A5051163337 @default.
• W2078235523 creator A5061634430 @default.
• W2078235523 creator A5075125041 @default.
• W2078235523 creator A5077837648 @default.
• W2078235523 date "2004-01-01" @default.
• W2078235523 modified "2023-10-16" @default.
• W2078235523 title "Clinical Properties of a Novel Liquid Intravenous Immunoglobulin: Studies in Patients with Immune Thrombocytopenic Purpura and Primary Immunodeficiencies" @default.
• W2078235523 cites W124404536 @default.
• W2078235523 cites W1970234075 @default.
• W2078235523 cites W1974416970 @default.
• W2078235523 cites W1987349895 @default.
• W2078235523 cites W1988154847 @default.
• W2078235523 cites W1991575564 @default.
• W2078235523 cites W2014373531 @default.
• W2078235523 cites W2014654838 @default.
• W2078235523 cites W2016132554 @default.
• W2078235523 cites W2027920097 @default.
• W2078235523 cites W2029709504 @default.
• W2078235523 cites W2034237856 @default.
• W2078235523 cites W2035800046 @default.
• W2078235523 cites W2037698344 @default.
• W2078235523 cites W2039105764 @default.
• W2078235523 cites W2049957378 @default.
• W2078235523 cites W2053549859 @default.
• W2078235523 cites W2058437162 @default.
• W2078235523 cites W2071614823 @default.
• W2078235523 cites W2083720153 @default.
• W2078235523 cites W2104382376 @default.
• W2078235523 cites W2137624749 @default.
• W2078235523 cites W2153202624 @default.
• W2078235523 cites W2157938748 @default.
• W2078235523 cites W219857140 @default.
• W2078235523 cites W2213836019 @default.
• W2078235523 cites W2315160100 @default.
• W2078235523 cites W2616639792 @default.
• W2078235523 doi "https://doi.org/10.1159/000079071" @default.
• W2078235523 hasPublicationYear "2004" @default.
• W2078235523 type Work @default.
• W2078235523 sameAs 2078235523 @default.
• W2078235523 citedByCount "8" @default.
• W2078235523 countsByYear W20782355232012 @default.
• W2078235523 crossrefType "journal-article" @default.
• W2078235523 hasAuthorship W2078235523A5004237078 @default.
• W2078235523 hasAuthorship W2078235523A5006932938 @default.
• W2078235523 hasAuthorship W2078235523A5029031558 @default.
• W2078235523 hasAuthorship W2078235523A5031052014 @default.
• W2078235523 hasAuthorship W2078235523A5034923377 @default.
• W2078235523 hasAuthorship W2078235523A5050816060 @default.
• W2078235523 hasAuthorship W2078235523A5051163337 @default.
• W2078235523 hasAuthorship W2078235523A5061634430 @default.
• W2078235523 hasAuthorship W2078235523A5075125041 @default.
• W2078235523 hasAuthorship W2078235523A5077837648 @default.
• W2078235523 hasConcept C126322002 @default.
• W2078235523 hasConcept C159654299 @default.
• W2078235523 hasConcept C197934379 @default.
• W2078235523 hasConcept C203014093 @default.
• W2078235523 hasConcept C203092338 @default.
• W2078235523 hasConcept C2776433325 @default.
• W2078235523 hasConcept C2778375690 @default.
• W2078235523 hasConcept C2779019163 @default.
• W2078235523 hasConcept C2779771385 @default.
• W2078235523 hasConcept C535046627 @default.
• W2078235523 hasConcept C71924100 @default.
• W2078235523 hasConcept C8891405 @default.
• W2078235523 hasConcept C89560881 @default.
• W2078235523 hasConcept C90924648 @default.
• W2078235523 hasConceptScore W2078235523C126322002 @default.
• W2078235523 hasConceptScore W2078235523C159654299 @default.
• W2078235523 hasConceptScore W2078235523C197934379 @default.
• W2078235523 hasConceptScore W2078235523C203014093 @default.
• W2078235523 hasConceptScore W2078235523C203092338 @default.
• W2078235523 hasConceptScore W2078235523C2776433325 @default.
• W2078235523 hasConceptScore W2078235523C2778375690 @default.
• W2078235523 hasConceptScore W2078235523C2779019163 @default.
• W2078235523 hasConceptScore W2078235523C2779771385 @default.
• W2078235523 hasConceptScore W2078235523C535046627 @default.
• W2078235523 hasConceptScore W2078235523C71924100 @default.
• W2078235523 hasConceptScore W2078235523C8891405 @default.
• W2078235523 hasConceptScore W2078235523C89560881 @default.
• W2078235523 hasConceptScore W2078235523C90924648 @default.
• W2078235523 hasIssue "3" @default.
• W2078235523 hasLocation W20782355231 @default.
• W2078235523 hasOpenAccess W2078235523 @default.
• W2078235523 hasPrimaryLocation W20782355231 @default.
• W2078235523 hasRelatedWork W2406283388 @default.
• W2078235523 hasRelatedWork W2509920429 @default.
• W2078235523 hasRelatedWork W2623127295 @default.
• W2078235523 hasRelatedWork W3022350387 @default.
• W2078235523 hasRelatedWork W3209587069 @default.
• W2078235523 hasRelatedWork W4205342467 @default.

• next